Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by tboron Jan 24, 2008 10:06pm

155 Views

Post# 14258893

RE: World Economic Forum Announces Technology Pio

Like I said Collins, I don't think you do fully understand.

How can they say it has been proven when there are no human trial reports yet?

As the holographic Dr. said to Will Smith in "I Robot"

"Now that,... is the right question."

The answer to which can be found in several posts from early last year by Amorak or Logix

Bullboard Posts

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta